Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Household transmission of SARS-CoV-2 infection in the Paris/Ile-de-France area.
Katlama C, Dudoit Y, Huyard J, Blanc C, Soulié C, Schneider L, Faycal A, Lenclume L, Hamani N, Qatib N, Tubiana R, Seang S, Sellem B, Costagliola D, Palich R, Valantin MA, Assoumou L. Katlama C, et al. Among authors: dudoit y. Eur J Clin Microbiol Infect Dis. 2022 Mar;41(3):445-454. doi: 10.1007/s10096-021-04345-9. Epub 2022 Jan 8. Eur J Clin Microbiol Infect Dis. 2022. PMID: 34997388 Free PMC article.
Neutrophils in antiretroviral therapy-controlled HIV demonstrate hyperactivation associated with a specific IL-17/IL-22 environment.
Campillo-Gimenez L, Casulli S, Dudoit Y, Seang S, Carcelain G, Lambert-Niclot S, Appay V, Autran B, Tubiana R, Elbim C. Campillo-Gimenez L, et al. Among authors: dudoit y. J Allergy Clin Immunol. 2014 Nov;134(5):1142-52.e5. doi: 10.1016/j.jaci.2014.05.040. Epub 2014 Jul 16. J Allergy Clin Immunol. 2014. PMID: 25042982 Clinical Trial.
Plasma concentrations of maraviroc and raltegravir after dual therapy in patients with long-term suppressed viraemia: ROCnRAL ANRS 157 study.
Lê MP, Soulié C, Assoumou L, Valantin MA, Duvivier C, Chas J, Ponscarme D, Marcelin AG, Calvez V, Katlama C, Peytavin G; ROCnRAL ANRS 157 Study Group. Lê MP, et al. J Antimicrob Chemother. 2015 Aug;70(8):2418-20. doi: 10.1093/jac/dkv113. Epub 2015 Apr 26. J Antimicrob Chemother. 2015. PMID: 25917348 Clinical Trial. No abstract available.
Virological factors associated with outcome of dual maraviroc/raltegravir therapy (ANRS-157 trial).
Soulié C, Assoumou L, Darty M, Rodriguez C, Donati F, Sayon S, Peytavin G, Valantin MA, Caby F, Schneider L, Canestri A, Costagliola D, Katlama C, Calvez V, Marcelin AG; ROCnRAL ANRS-157 Study Group. Soulié C, et al. J Antimicrob Chemother. 2015 Dec;70(12):3339-44. doi: 10.1093/jac/dkv280. Epub 2015 Sep 22. J Antimicrob Chemother. 2015. PMID: 26396157 Clinical Trial.
HIV therapeutic vaccine enhances non-exhausted CD4+ T cells in a randomised phase 2 trial.
Vieillard V, Combadière B, Tubiana R, Launay O, Pialoux G, Cotte L, Girard PM, Simon A, Dudoit Y, Reynes J, Rockstroh J, Garcia F, Gatell J, Devidas A, Yazdanpanah Y, Weiss L, Fätkenheuer G, Autran B, Joyeux D, Gharakhanian S, Debré P, Katlama C. Vieillard V, et al. Among authors: dudoit y. NPJ Vaccines. 2019 Jun 3;4:25. doi: 10.1038/s41541-019-0117-5. eCollection 2019. NPJ Vaccines. 2019. PMID: 31231551 Free PMC article.
Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen.
Palich R, Allavena C, Peytavin G, Soulie C, Tubiana R, Weiss L, Montoya Ferrer A, Duvivier C, Bouchaud O, Bottero J, Durand A, Lê MP, Marcelin AG, Dudoit Y, Assoumou L, Katlama C; ETRAL QD study group. Palich R, et al. Among authors: dudoit y. J Antimicrob Chemother. 2021 Jan 19;76(2):477-481. doi: 10.1093/jac/dkaa423. J Antimicrob Chemother. 2021. PMID: 33099638 Clinical Trial.
41 results